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Abstract
Background: Anthelmintics are one of the more commonly available classes of drugs to treat infections by
parasitic helminths (especially nematodes) in the human intestinal tract. As a result of their cost-effectiveness,
mass school-based deworming programs are becoming routine practice in developing countries. However,
experimental and clinical evidence suggests that anthelmintic treatments may increase susceptibility to other
gastrointestinal infections caused by bacteria, viruses, or protozoa. Hypothesizing that anthelmintics may increase
diarrheal infections in treated children, we aim to evaluate the impact of anthelmintics on the incidence of
diarrheal disease caused by viral and bacterial pathogens in school children in southern Vietnam.
Methods/design: This is a randomized, double-blinded, placebo-controlled trial to investigate the effects
of albendazole treatment versus placebo on the incidence of viral- and bacterial-induced diarrhea in 350
helminth-infected and 350 helminth-uninfected Vietnamese school children aged 6–15 years. Four hundred
milligrams of albendazole, or placebo treatment will be administered once every 3 months for 12 months. At
the end of 12 months, all participants will receive albendazole treatment. The primary endpoint of this study
is the incidence of diarrheal disease assessed by 12 months of weekly active and passive case surveillance.
Secondary endpoints include the prevalence and intensities of helminth, viral, and bacterial infections, alterations
in host immunity and the gut microbiota with helminth and pathogen clearance, changes in mean z scores of body
weight indices over time, and the number and severity of adverse events.
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Discussion: In order to reduce helminth burdens, anthelmintics are being routinely administered to children
in developing countries. However, the effects of anthelmintic treatment on susceptibility to other diseases,
including diarrheal pathogens, remain unknown. It is important to monitor for unintended consequences of
drug treatments in co-infected populations. In this trial, we will examine how anthelmintic treatment impacts
host susceptibility to diarrheal infections, with the aim of informing deworming programs of any indirect
effects of mass anthelmintic administrations on co-infecting enteric pathogens.
Trial registration: ClinicalTrials.gov: NCT02597556. Registered on 3 November 2015.
Keywords: Albendazole, Deworming, Soil-transmitted helminths, Diarrhea, Co-infection
Background
Soil-transmitted helminths (STH) are a group of intes-
tinal nematodes that can infect humans who come into
contact with helminth eggs or larvae in soil, food, or
water contaminated with feces. The four main species of
human STH are the roundworm, Ascaris lumbricoides;
the whipworm, Trichuris trichiura; and the hookworms,
Necator americanus and Ancylostoma duodenale. Recent
estimates suggest that A. lumbricoides infects 819
million people, T. trichiura 464.6 million people, and
hookworms 438.9 million people worldwide, with
greatest numbers occurring in sub-Saharan Africa,
Asia, and South America [1].
Most infections caused by STH are asymptomatic, es-
pecially when few worms are present. Heavy helminth
burdens, however, can lead to growth stunting, impaired
cognitive development, and malnutrition in infected
hosts [2]. When identified, heavily infected individuals
should always be dewormed because they are at highest
risk of morbidity and are a major source of environmen-
tal contamination with helminth eggs [3, 4]. However,
only a few hosts harbor such large burdens, while most
individuals harbor relatively few STH [5]. In fact, low-
intensity helminth infections may actually be beneficial
to hosts, as they may protect against detrimental effects
of other pathogens [6, 7] and autoimmune diseases [8].
Currently, in an effort to reduce helminth burdens, the
World Health Organization (WHO) recommends that
single-dose anthelmintics (400 mg albendazole or
500 mg mebendazole) be routinely administered to
school children either once a year in areas with STH
prevalence between 20 % and 50 % or twice a year in
areas with STH prevalence above 50 % [9]. This inter-
vention is aimed to reduce morbidity by reducing worm
burden [3, 4]. However, a recent Cochrane review and
meta-analysis found almost no evidence of benefits to
nutrition, cognitive development, school performance,
or survival in 45 mass deworming studies, although
there was no differentiation between infected and unin-
fected individuals in these analyses [10]. Additionally, in-
dividuals infected with STH also harbor many other
infectious agents, including virulent viral and bacterial
pathogens [11, 12], which may be indirectly impacted by
anthelmintic treatment, as demonstrated in studies of
naturally co-infected animals [13–15]. Current deworm-
ing programs focus solely on reducing the morbidity
caused by helminth infections and often fail to monitor
for indirect consequences of treatment on other patho-
gens. As human health reflects the integrated impact of
all infectious agents to which hosts are exposed, it is
crucial to monitor for unintended effects of mass drug
treatments in co-infected populations.
Recent experimental and clinical evidence suggests
that anthelmintic treatments may actually increase
host susceptibility to other gastrointestinal infections
(bacteria, viruses, or protozoa) [14–18]. For example,
a study by Blackwell et al. in lowland Bolivia found
that Giardia lamblia infection was less likely in helminth-
infected individuals compared to helminth-uninfected in-
dividuals and that treatment with anthelmintics marginally
increased the odds of future G. lamblia infections over
the course of 6 years [16]. This finding supports the re-
sults of a previous study, which suggested that treatment
for helminths may increase susceptibility to G. lamblia in-
fections in children in Bangladesh [19]. Two studies in
wild mice have shown that while a single oral dose of the
anthelmintic, ivermectin, significantly reduced nematode
infections, it resulted in a simultaneous increase in gastro-
intestinal coccidial protozoa [14, 15] and cestodes [15].
Additionally, anthelmintic treatment with pyrantel pamo-
ate in free-living yellow-necked mice was shown to in-
crease the abundance of specific ectoparasitic ticks [18].
In each of these cases, anthelmintic treatment resulted in
a concomitant increase of another co-infecting parasite
species, suggesting that the targeted helminths were
suppressing these infections [13]. As most individuals with
helminth infections are co-infected with multiple
parasite species, understanding the impact of mass
deworming programs on non-target pathogens, espe-
cially those posing high health risks, is warranted.
The aim of this study is to investigate the effects of an-
thelmintic treatment on diarrheal diseases caused by
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intestinal viral and bacterial pathogens in school chil-
dren in southern Vietnam. High rates of co-infections
are expected, due to the overlapping distributions and
similar routes of transmission of STH and diarrheal
pathogens. The shared intestinal niche between these
pathogens also suggests that direct and indirect interac-
tions will occur within the human gut, potentially
impacting the disease dynamics of each pathogen in un-
expected ways.
The proposed study will be conducted in Vietnam,
which has among the highest prevalence levels of human
STH of any Western Pacific country [20]. Diarrheal dis-
ease also remains a major cause of mortality and morbid-
ity in children in Vietnam, with 11 % of deaths in children
aged 0–5 years being due to diarrhea [21]. Recently, the
causative agents of diarrheal disease in children under
5 years of age in Ho Chi Minh City, Vietnam, were identi-
fied, with Norovirus, Rotavirus, Campylobacter, Salmon-
ella, and Shigella being the main pathogens isolated from
diarrheal patients [22]. Further analysis of a subset of
these samples by real-time polymerase chain reaction
(PCR) found STH eggs in 6/342 (1.8 %) diarrheal samples,
whereas 41/123 (33.3 %) of healthy control samples were
positive for STH (our unpublished data). Previous studies
have found that real-time PCR is sensitive enough to de-
tect even one STH egg in 200 mg of fecal material [23].
No statistical differences in demographics or personal
hygiene between helminth-infected and helminth-
uninfected individuals were present, including age, sex,
address, household size and income, water and food re-
sources, toilet type, probiotic usage, or hand-washing
practice. The significantly higher prevalence of STH in-
fections in healthy controls compared to diarrheal pa-
tients suggests that STH may be beneficial to children
in combating the pathogens that cause diarrhea. Thus,
the primary objective of this study is to investigate the
effects of 400 mg albendazole treatment on the inci-
dence of diarrheal disease caused by viral and bacterial
pathogens in school children in southern Vietnam. This
study will provide new insights into the role of co-
infections in the success of treatment strategies and
may inform public health policies to mitigate indirect
effects of mass deworming programs.
Methods/design
Study aims
We hypothesize that anthelmintic treatment with
400 mg albendazole will lead to an increase in the in-
cidence of diarrheal disease caused by viral or bacter-
ial pathogens, potentially due to alterations to the
host immune response and/or gut microbiota with
helminth removal. To test this hypothesis, we will
compare the incidence of diarrheal disease between
individuals receiving anthelmintic and placebo treatment
in a randomized, double-blinded, placebo-controlled trial
over the course of 12 months. Secondarily, this study will
determine the prevalence and intensities of helminth,
viral, and bacterial infections in the study location, alter-
ations in host immunity and the gut microbiota with hel-
minth and pathogen clearance, changes in mean z scores
of body weight indices over time, and the number and se-
verity of adverse events (AE). The study design presented
herein aims to investigate whether there are any indirect
effects of anthelmintic treatment on non-target diarrheal
pathogens, with the goal of informing deworming pro-
grams in co-infected populations.
Study area
This study will be conducted in three primary schools
in Cu Chi district in Ho Chi Minh City, Vietnam. Cu
Chi is a peri-urban district on the northwestern
border of Ho Chi Minh City. The climate of Cu Chi
district is temperate with two distinct seasons: a rainy
season from May to November and a dry season from
December to April. Agriculture is the main source of
income in the province. In 2010, Cu Chi district had
a population of approximately 355,822 people, with a
population density of 819 persons/km2 [24]. A prior
study indicated that hookworm infections are the pre-
dominant STH in this area, with most children ex-
periencing low infection intensities [25]. Although
parts of Vietnam participate in the national deworm-
ing program administered by the WHO, the primary
schools involved in this study have not provided
deworming medication to their school children since
January 2014 due to financial costs of the medication.
The schools have no plans to provide anthelmintic
medication to school children in the upcoming year.
Study design
This study is a randomized, double-blinded, placebo-
controlled trial designed to investigate the effects of
anthelmintic treatment (400 mg albendazole) on the
incidence of viral- and bacterial-induced diarrheal dis-
ease in school children aged 6–15 years in Cu Chi
district in Ho Chi Minh City, Vietnam. This study
was designed following the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
2013 statement (Additional file 1) and will have two
phases: (1) a baseline study and (2) a clinical trial.
The baseline study will assess the current prevalence
and intensity of STH infections in approximately
1800 school children in Cu Chi district. A stool sam-
ple will be collected for STH detection and quantita-
tion by real-time PCR and microscopy. Hematocrit
levels will be assessed from finger-prick blood draws
to monitor the risks of anemia with different STH in-
fections. From this baseline study, 350 helminth-
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infected and 350 helminth-uninfected individuals will be
selected from larger groups using a random number gen-
erator, then recruited and randomized to receive either
anthelmintic or placebo treatment once every 3 months
for 12 months. At the end of 12 months, all participants
will receive anthelmintic treatment. Weekly active and
passive surveillance of diarrheal cases will be conducted.
A study nurse will call the parents/guardians of each par-
ticipant weekly, asking if any incidence of diarrhea has oc-
curred. Participants will also inform the study nurse of
diarrheal cases through passive surveillance. Stool and
blood samples will also be collected throughout the study
for parasitological and immunological analyses (Fig. 1).
Eligibility
To be eligible for enrollment into the baseline study and
clinical trial, participants will need to be between 6 and
15 years of age and have written informed consent from
a parent or guardian. Children over 10 years of age will
themselves also be required to provide written assent in
order participate in this study. This age group was spe-
cifically selected because these individuals are expected
to have the highest intensity of STH infections [26] and
are targeted in mass deworming programs [27]. During
the baseline study, the child’s infection status with STH
and their hematocrit levels will be determined. A study
conducted in 2008 in Cu Chi district found that hook-
worms were the predominant STH in this area, with
most children experiencing low infection intensities
[25]. Since heavy hookworm infections may lead to
anemia [28], those children who are both positive for
hookworms and anemic will be excluded from the sub-
sequent clinical trial and will be treated with 400 mg
albendazole and iron supplements. However, a recent
Cochrane review and meta-analysis found no evidence
of any effect of deworming on the average hemoglobin
levels of children over 16 years of age in 45 randomized
controlled trials [10].
Inclusion of participants and informed consent
A letter of invitation will be sent home to all school
children attending three primary schools in Cu Chi
district in Ho Chi Minh City, Vietnam, inviting them
to participate in this study. A meeting will be held at
the schools so that parents can learn about the study.
Here, study staff will describe the purpose of the
Fig. 1 Flowchart of the study
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study, the study procedures, possible risks/benefits,
the rights and responsibilities of participants, and al-
ternatives to enrollment. Parents/guardians will be
given a participant information sheet that describes
the study using the local and lay language. They will
be asked if they understand the contents of the study
and will be given the chance to ask questions. Once
all questions have been answered satisfactorily, par-
ents/guardians who are interested in enrolling their
children in the study will be asked to sign an in-
formed consent. In the consent form, they will be
able to enroll their child in the baseline study only or
in both the baseline study and the clinical trial. They
will also consent to whether they agree to long-term
storage of the collected samples for research pur-
poses. The consent form will also explain to parents/
guardians that they are free to withdraw their child
from the study at any time and that information col-
lected up to their child’s withdrawal will be retained.
Children over 10 years of age will also be required to
provide written assent in order to participate in this
study. The study staff will also explain to all parents/
guardians interested in enrolling their child in both
the baseline study and the clinical trial that their
child may or may not be randomly selected into the
trial based upon the results from the baseline study.
Parents/guardians will be informed whether or not
their child is selected to participate in the clinical
trial. If the parents, guardians, or children are indeci-
sive about enrollment, they will be given up to 1 week
to consider entry into the study, after which point the
participant will no longer be eligible.
Routine follow-up and sample collection
Baseline study
All enrolled children will receive a study identification
(ID) number upon enrollment, which will be used to
label any collected sample and to help ensure the confi-
dentiality of the participant’s identity. The parent/
guardian of the enrolled child will be asked to complete
a short questionnaire regarding the child’s demograph-
ics, their daily habits, household information, and po-
tential sources of infection. A study nurse will also
collect information regarding the child’s weight and
height. A study nurse will train the parent/guardian on
stool collection and will provide them with a sterile
stool collection pot. The child will provide one stool
sample for helminth detection and for the detection of
viral and bacterial pathogens that cause diarrhea, using
real-time PCR and by the Kato-Katz method for mi-
croscopy. A finger-prick blood sample will also be col-
lected to calculate hematocrit levels as a measure of
anemia [29] (Fig. 1).
Clinical trial
From the baseline study, 350 helminth-infected and
350 helminth-uninfected children will be enrolled in
the subsequent clinical trial. These consented partici-
pants will complete a short questionnaire regarding
changes to their contact information, and a study
nurse will measure their height and weight. Albenda-
zole or placebo treatment will be administered once
every 3 months for 12 months. At the 12-month time
point, all participants will receive albendazole treat-
ment. Stool samples will be collected once every
3 months (immediately before any treatment is ad-
ministered) and 2 weeks after the first and third
treatments to evaluate the efficacy of anthelmintic
treatment in helminth removal and to quantify vari-
ation among individuals in their propensity to acquire
helminth infections. Parents/guardians will be con-
tacted weekly by phone to request information on
whether their child has experienced any diarrheal epi-
sodes in the preceding 7 days. When a participant
alerts the study nurse of a diarrheal episode, the
study nurse will travel to the individual’s home to
collect a stool sample and to administer a short ques-
tionnaire regarding the participant’s diarrheal symp-
toms and duration. A sterile stool collection pot will
also be left with the parents/guardians for a stool
sample collection 2 weeks after the last diarrheal epi-
sode. Four milliliters of venous blood will also be col-
lected by the study nurse once every 6 months to
measure hematocrit levels and any changes to im-
munity with helminth infection and removal over
time. A finger-prick blood sample will also be col-
lected in the third and the ninth month of the study
to measure hematocrit levels in all children (Fig. 1).
Data management
A case report form (CRF) will be used to collect data
for each participant. Paper CRFs will be used and
then entered into a password-protected, electronic
database. A central database has been developed to
ensure secure and confidential data management for
this study. All paper records will be stored securely
as per the Oxford University Clinical Research Unit
(OUCRU) and the Vietnamese Ministry of Health
guidelines and will be accessible to trial staff and au-
thorized personnel only. Participants will be identified
only by their initials and study ID or randomization
number on the CRF. Data entered into the electronic
database will be reviewed and verified by a second
study staff member to ensure accordance with paper
records. For quality control, all required fields in a
given section will need to be completed before pro-
gressing to subsequent sections, and entries from the
CRF into the database will be limited to the options
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on the questionnaire through pull-down menus, in
order to prevent the input of incorrect text. All electronic
devices for data entry will be password-protected and ac-
cessible only by authorized users.
Study medication and quality control
Albendazole is a benzimidazole anthelmintic that is
effective against a wide range of intestinal helminths
and is currently used in many mass deworming pro-
grams under WHO guidelines [30]. The 400 mg
albendazole used in this study will be purchased from
Imexpharm Pharmaceutical Joint Stock Corporation
(Cao Lanh, Vietnam) and will be manufactured under
the WHO good manufacturing process guidelines. Before
the start of the study, a random subset of albendazole and
placebo pills will be sent to an independent testing com-
pany to measure the quantities of ingredients in the medi-
cations to ensure that the drugs meet international quality
standards. Sachets with the active drug will contain one
chewable 400 mg albendazole pill (for easier consump-
tion). Matching placebo pills will lack the active ingredi-
ent, albendazole sulfoxide, but will otherwise contain the
same ingredients as the albendazole pill. All treatments
will look and taste alike. All treatments will remain at the
OUCRU with the study pharmacist and stored according
to manufacturer’s instructions until use. Every 3 months,
the medication will be securely transported to Cu Chi dis-
trict, and a trained study nurse will administer the medica-
tion to the participants with water, based upon the
participant’s study ID and randomization code found on
each medication sachet.
Treatment groups and duration of treatment
From the baseline study, 350 helminth-infected and 350
helminth-uninfected children will be randomized to
400 mg albendazole or placebo treatment in a 1:1 ratio
with equal randomization between helminth-positive
and helminth-negative individuals. The regimes will be
identical in both study groups, namely doses once every
3 months for the first 9 months. At the 12-month time
point, all participants will receive albendazole treatment.
For each dose, one sachet of chewable albendazole or
placebo treatment will be administered orally with water
to the enrolled participants by a trained study nurse.
Blinding and randomization
The trial participants, care providers, study investiga-
tors, outcome assessors, and data analysts will remain
blinded throughout the trial period of 12 months.
Treatment allocations will not be disclosed to the en-
rolled participants or study personnel until the con-
clusion of the study or in case of emergency. Only
the study pharmacist, who is not involved in field or
laboratory studies, will be privy to the treatment
allocations in order to prepare the treatment packages ac-
cordingly. Block randomization using a 1:1 randomization
ratio, stratification by helminth-infection status (infected
versus uninfected), and variable block sizes of 4 and 6,
respectively, will be used to randomize subjects into either
the anthelmintic or placebo group. The randomization list
will be generated according to OUCRU standard operat-
ing procedures. Briefly, a research biostatistician will es-
tablish a statistical code to generate the randomization list
and transfer it to the study pharmacist. The study pharma-
cist will change the random seed, i.e., the initialization of
the random number generator, in the statistical code in
order to blind the research biostatistician and then run
the code to prepare the final randomization list for
treatment preparation. The randomization list will be
password-protected and stored on a secure server to
which only the study pharmacist has access.
Randomization numbers, which correspond to a study
ID number and a sachet of study medication, will be
assigned to each enrolled participant in the clinical
trial in a strict numerical sequence with individual
school identifiers. Randomization numbers will be re-
corded on each participant’s CRF and used to identify
the participant’s corresponding blinded treatment
package. A total of four masked sachets containing ei-
ther anthelmintic or placebo treatment will be pre-
pared for each enrolled participant throughout the
clinical trial. All participants will receive albendazole
treatment at the conclusion of the study (month 12).
Laboratory methods
All samples from the baseline study will be labeled with
a study ID number, and all samples from the clinical trial
will be labeled with a study ID and randomization num-
ber to ensure anonymity. Samples will be stored at 4 °C
upon collection. At the end of each sampling day, all
samples will be transported to the OUCRU laboratory in
Ho Chi Minh City, Vietnam, aliquoted, and transferred
to a freezer at −80 °C until further analyses.
Parasite detection in stool samples
Nucleic acids will be extracted from fecal samples using
the MP FastDNA SPIN Kit for Soil, the NucliSENS easy-
MAG system, and/or the Roche MagNA pure 96 auto-
mated nucleic acid extraction machine. The extracted
deoxyribonucleic acid (DNA) and ribonucleic acid
(RNA) from all collected stool samples will be used as
templates for real-time PCR for helminth, bacteria, and
virus identification. Samples will be tested for A. lumbri-
coides, T. trichiura, N. americanus, A. duodenale, and
Strongyloides stercoralis for helminth infection, Shigella,
Campylobacter, and Salmonella for bacterial infection,
and Rotavirus and Norovirus for viral infections using
previously validated primers and probes [31–33]. Fecal
Leung et al. Trials  (2016) 17:279 Page 6 of 12
samples will also undergo microscopic investigation
using the Kato-Katz method for helminth detection and
egg quantification during the baseline study. Diarrheal
stool samples will be analyzed using the Luminex xTAG
Gastrointestinal Pathogen Panel for simultaneous de-
tection and identification of a wide array of intestinal
pathogens. Additionally, stool samples will be stored
and assayed retrospectively, where required, to detect
additional pathogens.
Determination of anemia in blood samples
Blood samples will be collected alternately via finger-
prick or venous draws to monitor hematocrit levels and
anemia in children for the baseline study and clinical
trial. Blood for anemia measures will be collected in ca-
pillary tubes and spun in a microhematocrit centrifuge.
The volume of red blood cells compared to the total
blood volume (red blood cells and plasma) will be mea-
sured using a manual microhematocrit reader. Anemia
will be defined using age-specific WHO thresholds ad-
justed on the basis of altitude. According to the WHO,
children aged 5–11 years who have a hematocrit less
than 0.34 and children aged 12–15 years who have a
hematocrit less than 0.36, are considered anemic [29].
Immune markers in venous blood samples
For the clinical trial, 20 % of enrolled participants will
have their venous blood samples separated into plasma,
peripheral blood mononuclear cells (PBMCs), and red
blood cells by density-gradient centrifugation at each
sample collection. A random number generator will be
used to equally subsample from the participants in each
arm of the study, and the samples from these partici-
pants will be processed for PBMCs at each venous blood
draw. The plasma will be removed and aliquoted for
storage at −20 °C for antibody detection against
parasite-specific antigens. PBMCs will be stimulated and
cultured at 37 °C for 48 hours for cytokine production.
The supernatants will be collected and stored at −20 °C
until assayed for cytokine content (e.g., production of
interferon gamma (IFNγ), tumor necrosis factor alpha
(TNFα), interleukin (IL)-4, IL-13, IL-10, IL-17, IL-22)
using bead-based immunoassays. Blood from the
remaining children will be centrifuged and separated
into plasma and cells upon collection. The plasma will
be removed and aliquoted for storage at −20 °C for cyto-
kine detection and for antibody detection against
parasite-specific antigens by enzyme-linked immuno-
sorbent assay.
Microbiota analyses by 16 s sequencing
DNA extracted from stool samples will be used for high-
throughput Illumina sequencing to generate sequence
data on the taxonomic composition of the gut
microbiota. Sequences will be assigned to operational
taxonomic units (OTUs), and the relative abundance
of microbial taxa will be calculated using the proportion
of OTUs present in each sample. Tests to identify signifi-
cant differences in the relative abundance of bacterial taxa
between groups will be conducted, and α-diversity and β-
diversity measurements will be made. Statistical
methods, combining dimension reduction using prin-
cipal coordinate analysis and regression techniques
for correlating microbiota analysis and parasite identi-
fication with immune data from blood, will be used
to generate a comprehensive portrait of cellular and
molecular events in the intestinal tract.
Endpoints
Primary endpoint
The primary endpoint of this study is the total incidence
of diarrheal disease, i.e., the total number of diarrheal
episodes assessed through weekly active and passive sur-
veillance during the 12-month study period. Diarrhea
will be defined according to WHO guidelines, which is
three or more loose stools in a 24-hour period or at least
one bloody/mucoid stool [34]. To be considered a new
episode of diarrhea, at least three intervening days of
normal stools without other gastrointestinal symptoms
need to have passed between diarrheal occurrences [35].
Secondary endpoints
The secondary endpoints are:
1. Prevalence and intensity of soil-transmitted helminth
infections at 0, 0.5, 3, 6, 6.5, 9, and 12 months, and
during and 2 weeks after cases of diarrhea
2. Prevalence and intensity of enteric viral and
bacterial infections that cause diarrhea at 0, 3, 6, 9,
and 12 months, and during and 2 weeks after cases
of diarrhea
3. Changes in fecal microbiota composition at 0, 0.5, 3,
6, 9, and 12 months, and during and 2 weeks after
cases of diarrhea
4. Changes in blood cytokine levels (TH1, TH2, TH17,
and Treg) at 0, 6, and 12 months
5. Antibody isotype responses to helminth and diarrheal
antigens at 0, 6, and 12 months
6. Mean z scores (height-for-age, weight-for-age,
weight-for-height) at 0 and 12 months
7. Number and severity of adverse events (AE) during
the 12-month study period
Sample size and statistical considerations
In southern Vietnam, approximately 30 % of school-aged
children are infected with at least one species of STH
[20]. This percentage was supported by our preliminary
study of helminth infections in healthy children in Ho
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Chi Minh City, Vietnam (our unpublished data). Most
data on diarrheal incidences due to enteric infections
have focused on children under 5 years of age. For the
bacterial pathogens, Shigella, Campylobacter, and
Escherichia coli, diarrheal rates in this age group range
from 3.3 cases/child per year in children under 1 year
old to 0.7 cases/child per year in 4-year-olds in Vietnam
[36]. Few studies have investigated the incidence of diar-
rheal events in children over 5 years of age. Considering
the diarrheal attack rate in 4-year-olds due to these three
pathogens, it is estimated that school children over
5 years of age will have a probability of at least 0.6 of ex-
periencing one or more diarrheal episodes due to any
viral or bacterial species during the 12-month follow-up
duration. The clinical trial is powered to detect a 15 %
absolute increase of this probability (from 0.6 to 0.75)
due to anthelmintic treatment in both the subgroups of
helminth-infected and helminth-uninfected participants.
For 80 % power at the two-sided 5 % significance level, a
total of 298 helminth-infected and 298 helminth-
uninfected participants will be needed. Of note, this
sample size calculation is conservative insofar that the
actual study endpoint measures the number of diarrheal
episodes and is thus more sensitive than the binary as-
sessment of whether at least one episode occurred or
not. To account for potential inadequacies in our as-
sumptions and some loss to follow-up, the sample size
was increased by 15 %. Thus, a total sample size of 700
participants: 350 helminth-infected and 350 helminth-
uninfected children, will be recruited from the baseline
study (using a random number generator to subsample
from those groups, as needed) to the clinical trial and
will be equally randomized to receive either anthelmintic
or placebo treatment. Assuming that approximately
30 % of school-aged children are infected with at least
one species of STH infection [20], to enroll 350
helminth-infected children, up to 1800 school children
will be enrolled in the baseline study, in order to ac-
count for any uncertainties in the helminth prevalence
during the baseline study and for decreased participant
enrollment for the clinical trial.
Statistical analysis
The main analysis population includes all randomized
participants, and the analysis will be conducted ac-
cording to the randomized treatment arm following
the intention-to-treat principle. Subgroup analyses ac-
cording to helminth infection status at enrollment
(infected versus uninfected) will also be performed for
all endpoints.
The primary endpoint, the number of diarrheal epi-
sodes per subject, will be compared between the two
study arms based on mixed-effects Poisson regression
models, with treatment as the main covariate and
adjustment for helminth infection status at enrollment
(infected versus uninfected). To account for subjects
lost to follow-up, the subject’s (log-transformed)
follow-up duration will be included as an offset in the
Poisson regression model. Moreover, to account for
potential heterogeneity (i.e., larger between-participant
variability than expected by the Poisson regression
model), the participant variable will be included as a
random effect in the model. If necessary, a random
effect of family or household will also be included to
account for non-independence of siblings or other co-
inhabitants of a household. In a second step, the ef-
fect of the following covariates on diarrheal incidence
will be explored: age, sex, body mass index, and
household characteristics (e.g., type of water supply).
A random effect of individual will be included to ac-
count for non-independence of repeated diarrheal epi-
sodes for a given individual. Additionally, the effect of
helminth infection and helminth infection intensity,
as determined from longitudinal stool samples, on
diarrheal incidence will be investigated.
For the secondary endpoints, the proportion of partici-
pants with STH and enteric viral and bacterial infec-
tions, as well as the infection intensities at each time
point, will be summarized and visualized as line-plots
over time. Formal comparisons between the treatment
arms will be based on logistic mixed-effects models for
proportions and linear mixed-effects models for (log-
transformed) intensities using the same covariates and
random effects as for the primary endpoint. The baseline
measurements will be included in the analysis, but mod-
eled as not depending on treatment arm. For the main
comparison between treatment arms, only stool samples
from scheduled visits will be included, as stool samples
collected 2 weeks after diarrheal episodes may be un-
equally distributed between treatment arms. However,
these additional stool samples will be included in the ex-
ploratory analyses. The effect of additional household
and environmental factors present at baseline on
helminth, viral, and bacterial infections will also be in-
vestigated using the same statistical modeling approach
outlined above.
The taxonomic composition of the gut microbiota
will be analyzed before and after helminth infection,
anthelmintic treatment, and diarrhea and will be com-
pared with individual baseline levels, between the two
treatment arms, and between helminth-infected and
helminth-uninfected individuals. The mothur pipeline
[37] will be used to detect microbial composition and
diversity between and within samples based upon the
proportion of OTUs in each sample and to apply ap-
propriate corrections for any differences driven by
rare taxonomic groups of microbes. Tests, such as
the LDA Effect Size (LEfSe) algorithm [38], will be
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used to identify significant differences in bacterial
taxa between the different groups of interest.
Cytokine levels and antibody profiles in response to
parasite-specific antigens will be analyzed from longitu-
dinally collected blood samples. Cytokine and antibody
data will be log-transformed for all analyses, and linear
mixed-effects modeling for analysis will be conducted
as outline above. Additionally, changes in height-for-
age, weight-for-age, and weight-for-height z scores be-
tween baseline and 12 months will be compared between
the two treatment arms based on linear regression with
adjustment for the baseline z score. Random effects to ac-
count for non-independence of siblings or other co-
inhabitants from the same household will be included if
necessary. Additionally, the overall number of participants
with at least one adverse event (AE) or serious adverse
event (SAE), respectively, will be compared between the
two study arms using Fisher’s exact test. Descriptive tables
will be used to summarize the frequency of all recorded
AEs and SAEs by arm.
Reporting of serious adverse events
All grade three to grade five AEs and SAEs will be re-
corded on the participant’s CRF. AEs are graded accord-
ing to their severity from 0 to 5 according to the
Common Terminology Criteria for Adverse Events from
National Cancer Institute [39]. A study physician will
use clinical judgment to assess whether the AE/SAE is
drug and/or study-related, or if it is due to the natural
history of the underlying condition or disease. If a par-
ticipant experiences a SAE, the study physician will in-
form the principal investigator and complete the specific
documentations and the CRF. All SAEs will be reported
to the Institutional Review Boards (IRBs) of reference,
sponsors, and the Data and Safety Monitoring Board for
this study.
Data monitoring
The study will be overseen by an independent Data
and Safety Monitoring Board (DSMB), who will re-
view unblinded study data at bi-annual safety interim
analyses, once before the initiation of the study and
once at the 6-month time point, and can recommend
stopping or modification of the trial in case accruing
evidence suggests that continuing the study would be
unethical. The constituents of the DSMB will have no
role in the planning, conduct, or implementation of
the trial itself and will serve only as a third party in-
ternal review of data and safety. The DSMB may rec-
ommend termination or modification of the study if
preliminary data indicate beyond a reasonable doubt
that anthelmintic treatment increases the total inci-
dence of diarrheal disease (primary endpoint) or if
the observed diarrheal incidence in either treatment
group is at least tripled compared to the other. The
Haybittle-Peto boundary, requiring a p value <0.001
at interim analysis to consider stopping for superiority
of placebo, will be used as a guidance. The DSMB
may also recommend termination or modification if
preliminary data clearly suggest that withholding an-
thelmintic treatment (i.e., the placebo group) is harmful in
terms of anemia. A less conservative p value <0.01 in the
direction of harm for either of these endpoints will be
used as guidance. The DSMB recommendation should
not be based purely on statistical tables and p values, but
also requires clinical judgment.
Discussion
The WHO plans for the regular administration of an-
thelmintics to 75 % of all school-aged children at risk of
helminth-induced morbidity by 2020 [40]. Given the
rapid expansion of single-dose mass administration of
anthelmintic therapy at a global level, studies assessing
the impact of anthelmintic treatments on other patho-
gens are needed. Recently, anthelmintic trials have
begun to monitor for altered risks of malarial infections
in dewormed individuals [41–43]. However, studies in-
vestigating the impact of anthelmintic treatments on
pathogens other than the targeted helminths remain
rare. Here, we plan to investigate whether anthelmintic
treatments alter the incidence of diarrheal disease
caused by viral and bacterial pathogens in school chil-
dren in southern Vietnam.
Two types of single-dose anthelmintics, 400 mg
albendazole and 500 mg mebendazole, are recom-
mended by the WHO for STH control [30]. For STH,
the efficacy of albendazole and mebendazole varies
depending on helminth species. The cure rates after a
single dose of 400 mg albendazole are around 96 %
for A. lumbricoides, 34 % for T. trichiura, and 69 %
for hookworms [44]. With a single dose of 500 mg
mebendazole, the cure rates for infection by A. lum-
bricoides, T. trichiura, and hookworms are around
93 %, 40 % and 31 %, respectively. Due to the higher
cure rate of albendazole for hookworm infections,
which are the predominant STH infections in Cu Chi
district [25], and to follow the previous medication
used in school-based deworming programs in this
area, 400 mg albendazole was selected to be used in
this study. As part of the clinical trial, we will also
collect stool samples 2 weeks after the first and third
treatments, which will allow us to further investigate
the efficacy of albendazole in reducing STH burdens
in Cu Chi district. Irrespective of the trial outcome,
the data generated from this study will generate valu-
able information regarding the rates of helminth ac-
quisition, intensities of helminth infections, incidence
of diarrhea, and efficacy of anthelmintic treatments in
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school-aged children in Cu Chi district, which can in-
form Vietnam health officials when designing future
public health programs.
Re-infection occurs rapidly after all types of deworm-
ing. Within 3 months post treatment, approximately one
third of treated individuals are re-infected with STH and
more than 50 % of individuals are typically re-infected
6 months post treatment [45]. In order to decrease the
chances of re-infection in the anthelmintic arm, we will
administer anthelmintic and placebo treatments once
every 3 months in contrast to current school-based
deworming programs in Vietnam, which administer an-
thelmintic treatments once every 6 months. The in-
creased frequency of anthelmintic administration poses
no known health risk to the individual [46]. This study
design will help to minimize the helminth burden in
those individuals in the anthelmintic arm and thus in-
crease the chances of observing any potential effect of
anthelmintics on diarrheal incidence.
As it is difficult to accurately assess the burden of
diarrheal disease [47], an important strength of this
study is the active surveillance of diarrheal cases that
will be conducted during the trial. We will monitor
for incidences of diarrhea through weekly active and
passive surveillance. A study nurse will call the par-
ents/guardians of each participant weekly, asking if
any incidence of diarrhea has occurred. Participants
will also inform the study nurse of diarrheal cases
through passive surveillance. We will also collect
stool samples and information regarding diarrheal
symptoms with each diarrheal episode. Most studies
on diarrhea focus on children under 5 years of age,
and there is currently a dearth of studies reporting
on diarrhea in school-aged children [48]. This study
will provide valuable information regarding the causa-
tive agents and frequency of diarrhea in this age
group in Cu Chi district of Ho Chi Minh City, Vietnam.
While the primary endpoint of the study is the inci-
dence of diarrheal disease assessed by 12 months, the
sample collections in this trial will also help to disen-
tangle potential mechanisms by which helminths may
be altering the incidence of viral- and bacteria-induced
diarrhea. Helminths can affect both the activation of
the human immune system and the composition of the
gut microbiota (e.g., [49, 50]), and these alterations may
impact the colonization or invasion of enteric viral and
bacterial pathogens that share the same intestinal niche.
The blood and stool samples collected in this study will
help to assess biological differences in immune function
and gut microbial communities between infected and
uninfected individuals and between treatment groups,
which may elucidate potential mechanisms by which
helminths interact with diarrheal pathogens in the
human gut.
Ultimately, this study will provide an important first
test of whether anthelmintic treatment has unin-
tended effects on the health of school children and
their subsequent risks of infections due to enteric
viral and bacterial pathogens. This study is timely and
much needed, as diarrhea remains a major concern
for child health worldwide, as deworming programs
are becoming routine in developing countries, and as
growing experimental evidence suggests that anthel-
mintic treatments may increase host susceptibility to
other infections (bacteria, viruses, or protozoa) [14–18].
We aim to investigate whether current mass administra-
tions of anthelmintic treatments indirectly impact the dis-
ease dynamics of co-infecting pathogens by focusing on
diarrheal pathogens that inhabit the same intestinal niche
as STH. Our results will provide new insights into the role
of co-infections in the success of treatment strategies in
developing countries and will elucidate the importance of
both the microbiota and macrobiota in human health.
Further relevant aims of this study are to inform public
health policies of potential indirect effects of mass
deworming programs on other co-infecting pathogens
and to inform WHO recommendations on anthelmintic
dose regimens for Cu Chi district and beyond.
Trial status
This study has started participant recruitment.
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